Developer docs
API playgroundTry for free, no card

Search company profiles

Arcera Life Sciences

Full company profile

uuid006f8pt

Namestring
Arcera Life Sciences
Legal namestring
Arcera Life Sciences LLC OPC
Company typeenum
Private
Founded yearint
2024
Descriptiontext

Arcera Life Sciences is a privately held global life sciences holding company headquartered in Abu Dhabi, United Arab Emirates, established by sovereign investor ADQ in 2024. The company consolidates three legacy pharmaceutical businesses — Acino (Swiss-founded, emerging markets specialty), Amoun Pharmaceutical Company (Egypt), and Birgi Mefar Group (Türkiye-based CDMO for sterile solutions and injectables) — under a unified operating model effective January 2025, organized into Arcera General Medicines and Arcera TechOps divisions.

The company develops, manufactures, and commercializes a portfolio of more than 2,000 branded medicines spanning oncology, neuroscience, cardiometabolic disease, rare diseases, and anti-infectives, with over 100 focus brands. Manufacturing and packaging operations span eight countries including EU GMP-certified facilities in Ukraine and Switzerland and ISO 14001-certified sites in Ukraine, South Africa, Türkiye, and Egypt. Notable products include Ariprazol (aripiprazole antipsychotic, EU-qualified with Latvia launch in 2026), a breakthrough intravenous antibiotic targeting antimicrobial resistance (UAE launch 2026), and the licensed AR1001 investigational Alzheimer's therapy. Arcera operates its own digital platforms, including the CATALYST AI-enabled decision intelligence platform for healthcare professional engagement and the IQVIA SmartSolve eQMS implemented across 12 locations.

The business model combines direct pharmaceutical product sales (reaching patients in 120+ markets), B2B contract manufacturing and out-licensing services (active in 75 countries), and licensing/supply agreements for innovative therapies. Revenue is generated across diverse customer segments including healthcare providers, government health systems, and pharmaceutical companies seeking emerging market access. Distribution combines direct enterprise sales (29 country offices) with channel/distribution partnerships, including a strategic collaboration with Fosun Pharma for Chinese biotech access and an MoU with M42 for biopharma localization in Abu Dhabi. Arcera employs approximately 6,000-6,500 people globally and operates with sovereign backing from ADQ, which is using the company as the anchor platform for Abu Dhabi's Healthcare Life Sciences Vision 2030.

Short descriptiontext

Arcera Life Sciences is an Abu Dhabi-based, ADQ-owned global pharmaceutical holding company consolidating Acino, Amoun Pharmaceutical, and Birgi Mefar Group to develop, manufacture, and commercialize 2,000+ medicines across 120+ markets, with EU GMP-certified manufacturing in eight countries and a portfolio spanning branded generics, innovative therapies, and contract manufacturing services.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersAbu Dhabi, United Arab Emirates
HQ citystring
Abu Dhabi
HQ countrystring
United Arab Emirates
HQ regionstring
Middle East
Markets served

Serves global market

Offices22 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
branded generic medicines, pharmaceutical contract manufacturing, pharmaceutical licensing partnerships, emerging market pharmaceuticals, sterile injectables manufacturing
Industry3 codes
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical Manufacturing
GTM motion4 records

Each record includes

Type, Description, Source

Revenue model3 records
1Pharmaceutical Product Sales
TypeOne Time License
Description

Development, manufacturing, and commercialization of innovative and proven medicines across 2,000+ products, reaching patients in over 120 markets through direct sales and distribution networks.

arceralifesciences.com
2Contract Manufacturing Services
TypeProfessional Services
Description

B2B contract manufacturing and out-licensing services to pharmaceutical companies, providing manufacturing capabilities across 8 countries including sterile solutions and injectables.

arceralifesciences.com:443
3Licensing and Supply Agreements
TypeLicensing Royalties
Description

Revenue through exclusive licensing and supply agreements for innovative therapies, such as the AR1001 Alzheimer's treatment from AriBio and neuroscience collaborations with Fosun Pharma.

arceralifesciences.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels5 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Ariprazol
Description

Prescription antipsychotic medicine (aripiprazole) for treatment of schizophrenia and bipolar disorder.

arceralifesciences.com
+1 more record
Core offering1 text field

Arcera Life Sciences develops, manufactures, and commercializes over 2,000 branded generic and innovative pharmaceutical medicines across therapeutic areas including oncology, neuroscience, cardiometabolic, and rare diseases. The company operates through manufacturing facilities in eight countries and reaches patients in more than 120 markets via direct commercial operations, while also providing B2B contract manufacturing services to third-party pharmaceutical companies across 75 countries. Through licensing agreements and strategic partnerships, Arcera advances innovative therapies such as the AR1001 Alzheimer's treatment from AriBio.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Over 40% of UAE portfolio sales from domestically manufactured products
+3 more records
Product overview1 text field

Arcera Life Sciences is a global pharmaceutical company headquartered in Abu Dhabi, established by ADQ. The company develops, manufactures, and commercializes over 2,000 branded medicines across multiple therapeutic areas. Arcera operates through three main subsidiaries: Acino, Amoun Pharmaceutical Company, and Birgi Mefar Group. The company offers products in branded generics, off-patent originator medicines, innovative medicines, and over-the-counter products, supported by manufacturing and packaging facilities in eight countries. The portfolio includes prescription pharmaceuticals (Ariprazol antipsychotic), anti-infectives (breakthrough AMR-targeting intravenous antibiotic), and the company leverages technology platforms including the CATALYST decision intelligence system and SmartSolve eQMS for operational excellence.

Product and service5 records
1Ariprazol (aripiprazole)
CategoryPrescription Pharmaceuticals - Neuroscience
Description

Prescription antipsychotic medication indicated for the treatment of schizophrenia and bipolar disorder in adults, also used as part of broader therapeutic approaches for post-traumatic stress disorder. Received EU qualification release and launched commercially in Latvia with inclusion in Latvia's reimbursement program, manufactured at Acino Ukraine's EU GMP-certified facility.

2Breakthrough Intravenous Antibiotic for Antimicrobial Resistance (AMR)
CategoryPrescription Pharmaceuticals - Anti-infectives
Description

Intravenous antibiotic designed to restore efficacy against multidrug-resistant bacteria, including Extended Spectrum Beta-Lactamase-producing pathogens. Offers physicians a new treatment option against AMR, with UAE launch and regulatory approval progressing across GCC and registration plans for South Africa expected early 2027.

3Branded Generic and Innovative Medicines Portfolio
CategoryPharmaceutical Products
Description

Diversified portfolio of over 2,000 branded generic, off-patent originator, and innovative medicines across therapeutic areas including oncology, neuroscience, cardiometabolic diseases, and rare diseases. Reaches patients in 120+ markets across five continents through direct commercial operations and licensing agreements.

4Pharmaceutical Contract Manufacturing Services
CategoryContract Manufacturing Services
Description

B2B contract manufacturing services for pharmaceutical companies requiring manufacturing capabilities for sterile solutions, injectables, and generic medicines. Services provided across 75 countries leveraging EU GMP-certified facilities in Switzerland, Ukraine, T\u00fcrkiye, South Africa, Egypt, and other locations.

5Pharmaceutical Licensing and Supply Services
CategoryLicensing and Partnership Services
Description

Exclusive licensing and supply agreements enabling pharmaceutical and biotech partners to commercialize therapies across multiple international markets. Examples include the AriBio AR1001 Alzheimer's therapy agreement and neuroscience collaborations with Fosun Pharma. Arcera provides regulatory, commercial, and market access expertise in emerging markets often not prioritized in early global launches.

Scale indicator11 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-06-03
Description

M42 and Arcera signed a strategic MoU to advance biopharma localization, clinical development, and next-generation healthcare innovation in Abu Dhabi. The collaboration focuses on four pillars: genomics-informed therapeutic development, clinical development acceleration, advanced biobanking and regenerative medicine, and digital/AI-enabled transformation. Aligned with Department of Health Abu Dhabi's efforts to reinforce Emirate's position as a global hub for life sciences innovation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-05
Description

MoU to strengthen pharmaceutical manufacturing capabilities in UAE through collaboration on local manufacturing, talent development, research and innovation, and strategic supply of medical products. Partnership supports Emiratization through training programs, technical exchanges, and workshops. Contributes to expanding local manufacturing capacity and strengthening UAE's strategic stockpile of medical products.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2026-04-28
Description

Arcera and Fosun Pharma signed MoU for long-term strategic collaboration focused on licensing, frontier technology incubation, and neuroscience innovation. Initial focus on licensing opportunities in oncology, neuroscience, rare diseases, and cardiometabolic disease. Exploration of joint ventures to localize cutting-edge biotechnology including biologics, radiopharmaceuticals, siRNA therapies, and cell and gene therapies in UAE. Aligned with China-UAE bilateral partnership and Abu Dhabi's Healthcare Life Sciences Vision 2030.

Strategic tierSupportingTypeImplementation/ SI/ Consulting PartnerAnnounced on2026-03-05
Description

Partnership for implementation of new electronic Quality Management System (eQMS) consisting of six SmartSolve modules across 12 locations and corporate functions. Successfully implemented in nine months, strengthening quality, efficiency, and collaboration across manufacturing network.

Strategic tierSupportingTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

Academic partner hosting Arcera's Catalyst Forum at NYU Abu Dhabi, bringing together healthcare, academic, government, and industry leaders to discuss AI-powered healthcare transformation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-03
Description

Collaboration through M42 partnership framework to leverage genomics data, support clinical development, and align with DoH's efforts to reinforce Abu Dhabi as global hub for life sciences innovation.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-01-31
Description

Strategic MoU to advance health economics and outcomes research (HEOR) and health technology assessment (HTA) in UAE. Partnership focuses on enhancing research capabilities, building national expertise, and supporting evidence-based decision-making. Also includes collaboration on capacity building, career development, and mentorship. Supports UAE's ambition for healthcare excellence and life sciences leadership.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-06-10
Description

Exclusive licensing and supply agreements for AR1001, an investigational therapy for Alzheimer's disease. Arcera will advance development and commercialize the therapy across multiple international markets. Collaboration reflects commitment to identifying promising therapies and accelerating patient access in markets often not prioritized in early stages of global product launches.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2025-06-10
Description

Exclusive licensing and supply agreements for AR1001, an investigational therapy for Alzheimer's disease. Arcera will advance development and commercialize across multiple international markets, particularly emerging markets not prioritized in early global launches.

10LG Chem
Strategic tierSupportingTypeChannel Partner/ Reseller/ DistributorAnnounced on2024-07-24
Description

Exclusive agreement for marketing, commercialization, and distribution of Hyruan One in Brazil for osteoarthritis treatment, and Zemiglo and Zemimet SR (Zemiduo SR in Mexico) for type 2 diabetes in Latin American markets.

arceralifesciences.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian generic and specialty pharmaceutical company with strong emerging markets footprint. Comparable through large-scale branded generics, complex injectables manufacturing, and emerging markets distribution capability.

TypeDirect peer
Description

South African pharmaceutical leader with operations across Africa, Latin America, and Asia. Comparable to Arcera through its emerging markets focus, branded generics portfolio, and complex manufacturing footprint in multiple jurisdictions.

TypeDirect peer
Description

Indian pharmaceutical major with strong presence in Africa, emerging markets, and respiratory/chronotherapeutics. Directly comparable through its emerging markets commercial infrastructure, branded generics model, and ARV/oncology therapeutic focus areas.

TypeDirect peer
Description

Jordan-headquartered branded generics and injectables manufacturer with deep MEA and emerging markets presence. Directly comparable to Arcera through similar geographic focus, branded generics portfolio, and CDMO/injectables capabilities.

TypeDirect peer
Description

Indian global pharmaceutical company with significant emerging markets presence across CIS, Africa, and Latin America. Comparable through diversified branded generics portfolio, CDMO services, and biosimilars pipeline.

TypeBroad incumbent
Description

Global leader in generics and specialty medicines with extensive emerging markets presence. Comparable through broad generics portfolio and complex manufacturing, though operates at significantly larger scale and is publicly listed.

7Sandoz (Novartis)
TypeBroad incumbent
Description

Global generics and biosimilars business carved out of Novartis with worldwide distribution. Comparable through diversified generics portfolio and biologics manufacturing capabilities, though Sandoz is a global incumbent with much broader geographic reach.

8Julphar (Gulf Pharmaceutical Industries)
TypeDirect peer
Description

UAE-headquartered pharmaceutical manufacturer with MEA regional focus. Directly comparable to Arcera as the most prominent homegrown UAE pharma player with similar GCC distribution model and branded generics portfolio.

TypeDirect peer
Description

Indian pharmaceutical company with branded generics, complex generics, and biosimilars portfolio across emerging markets. Comparable through similar therapeutic focus areas and emerging markets commercial model.

TypeBroad incumbent
Description

Global generics and biosimilars giant formed from Mylan-Upjohn merger with worldwide reach. Comparable through branded generics and off-patent originator medicines focus, though Viatris operates at much larger global scale across all major markets.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers4 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles17 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries14 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Arcera Life Sciences

Pharmaceutical Manufacturingarceralifesciences.com

Arcera Life Sciences is an Abu Dhabi-based, ADQ-owned global pharmaceutical holding company consolidating Acino, Amoun Pharmaceutical, and Birgi Mefar Group to develop, manufacture, and commercialize 2,000+ medicines across 120+ markets, with EU GMP-certified manufacturing in eight countries and a portfolio spanning branded generics, innovative therapies, and contract manufacturing services.

What Arcera Life Sciences does

Arcera Life Sciences is a privately held global life sciences holding company headquartered in Abu Dhabi, United Arab Emirates, established by sovereign investor ADQ in 2024. The company consolidates three legacy pharmaceutical businesses — Acino (Swiss-founded, emerging markets specialty), Amoun Pharmaceutical Company (Egypt), and Birgi Mefar Group (Türkiye-based CDMO for sterile solutions and injectables) — under a unified operating model effective January 2025, organized into Arcera General Medicines and Arcera TechOps divisions.

The company develops, manufactures, and commercializes a portfolio of more than 2,000 branded medicines spanning oncology, neuroscience, cardiometabolic disease, rare diseases, and anti-infectives, with over 100 focus brands. Manufacturing and packaging operations span eight countries including EU GMP-certified facilities in Ukraine and Switzerland and ISO 14001-certified sites in Ukraine, South Africa, Türkiye, and Egypt. Notable products include Ariprazol (aripiprazole antipsychotic, EU-qualified with Latvia launch in 2026), a breakthrough intravenous antibiotic targeting antimicrobial resistance (UAE launch 2026), and the licensed AR1001 investigational Alzheimer's therapy. Arcera operates its own digital platforms, including the CATALYST AI-enabled decision intelligence platform for healthcare professional engagement and the IQVIA SmartSolve eQMS implemented across 12 locations.

The business model combines direct pharmaceutical product sales (reaching patients in 120+ markets), B2B contract manufacturing and out-licensing services (active in 75 countries), and licensing/supply agreements for innovative therapies. Revenue is generated across diverse customer segments including healthcare providers, government health systems, and pharmaceutical companies seeking emerging market access. Distribution combines direct enterprise sales (29 country offices) with channel/distribution partnerships, including a strategic collaboration with Fosun Pharma for Chinese biotech access and an MoU with M42 for biopharma localization in Abu Dhabi. Arcera employs approximately 6,000-6,500 people globally and operates with sovereign backing from ADQ, which is using the company as the anchor platform for Abu Dhabi's Healthcare Life Sciences Vision 2030.

Arcera Life Sciences firmographics

Firmographics
Name
Arcera Life Sciences
Legal name
Arcera Life Sciences LLC OPC
Website
https://arceralifesciences.com
Company type
Private
Founded year
2024
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Arcera Life Sciences is an Abu Dhabi-based, ADQ-owned global pharmaceutical holding company consolidating Acino, Amoun Pharmaceutical, and Birgi Mefar Group to develop, manufacture, and commercialize 2,000+ medicines across 120+ markets, with EU GMP-certified manufacturing in eight countries and a portfolio spanning branded generics, innovative therapies, and contract manufacturing services.
Ownership category
akta.pro rank

Arcera Life Sciences industry classification

Industry
Product category
Pharmaceutical Manufacturing
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAAAE
Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity)
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAIAIAH
Rare Cardiovascular & Vascular Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAH
Regulatory Strategy & IND/NDA/BLA Submissions Support
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Branded generic medicines
  • Pharmaceutical contract manufacturing
  • Pharmaceutical licensing partnerships
  • Emerging market pharmaceuticals
  • Sterile injectables manufacturing

Where Arcera Life Sciences is headquartered

Location

Headquarters

HQ city
Abu Dhabi
HQ country
United Arab Emirates
HQ region
Middle East

Offices22 records

Markets served

Arcera Life Sciences business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

  1. Pharmaceutical Product Sales: Development, manufacturing, and commercialization of innovative and proven medicines across 2,000+ products, reaching patients in over 120 markets through direct sales and distribution networks.
  2. Contract Manufacturing Services: B2B contract manufacturing and out-licensing services to pharmaceutical companies, providing manufacturing capabilities across 8 countries including sterile solutions and injectables.
  3. Licensing and Supply Agreements: Revenue through exclusive licensing and supply agreements for innovative therapies, such as the AR1001 Alzheimer's treatment from AriBio and neuroscience collaborations with Fosun Pharma.

Go-to-market motion4 records

Distribution channels5 records

Marketing channels7 records

Arcera Life Sciences product offering

Product offering

Core offering

Arcera Life Sciences develops, manufactures, and commercializes over 2,000 branded generic and innovative pharmaceutical medicines across therapeutic areas including oncology, neuroscience, cardiometabolic, and rare diseases. The company operates through manufacturing facilities in eight countries and reaches patients in more than 120 markets via direct commercial operations, while also providing B2B contract manufacturing services to third-party pharmaceutical companies across 75 countries. Through licensing agreements and strategic partnerships, Arcera advances innovative therapies such as the AR1001 Alzheimer's treatment from AriBio.

Product overview

Arcera Life Sciences is a global pharmaceutical company headquartered in Abu Dhabi, established by ADQ. The company develops, manufactures, and commercializes over 2,000 branded medicines across multiple therapeutic areas. Arcera operates through three main subsidiaries: Acino, Amoun Pharmaceutical Company, and Birgi Mefar Group. The company offers products in branded generics, off-patent originator medicines, innovative medicines, and over-the-counter products, supported by manufacturing and packaging facilities in eight countries. The portfolio includes prescription pharmaceuticals (Ariprazol antipsychotic), anti-infectives (breakthrough AMR-targeting intravenous antibiotic), and the company leverages technology platforms including the CATALYST decision intelligence system and SmartSolve eQMS for operational excellence.

Differentiator

Problem solved

Functional benefit

Brands

  • Ariprazol: Prescription antipsychotic medicine (aripiprazole) for treatment of schizophrenia and bipolar disorder.
  • Arcera's AMR Antibiotic

Products and services

  • Ariprazol (aripiprazole) Prescription antipsychotic medication indicated for the treatment of schizophrenia and bipolar disorder in adults, also used as part of broader therapeutic approaches for post-traumatic stress disorder. Received EU qualification release and launched commercially in Latvia with inclusion in Latvia's reimbursement program, manufactured at Acino Ukraine's EU GMP-certified facility.
  • Breakthrough Intravenous Antibiotic for Antimicrobial Resistance (AMR) Intravenous antibiotic designed to restore efficacy against multidrug-resistant bacteria, including Extended Spectrum Beta-Lactamase-producing pathogens. Offers physicians a new treatment option against AMR, with UAE launch and regulatory approval progressing across GCC and registration plans for South Africa expected early 2027.
  • Branded Generic and Innovative Medicines Portfolio Diversified portfolio of over 2,000 branded generic, off-patent originator, and innovative medicines across therapeutic areas including oncology, neuroscience, cardiometabolic diseases, and rare diseases. Reaches patients in 120+ markets across five continents through direct commercial operations and licensing agreements.
  • Pharmaceutical Contract Manufacturing Services B2B contract manufacturing services for pharmaceutical companies requiring manufacturing capabilities for sterile solutions, injectables, and generic medicines. Services provided across 75 countries leveraging EU GMP-certified facilities in Switzerland, Ukraine, T\u00fcrkiye, South Africa, Egypt, and other locations.
  • Pharmaceutical Licensing and Supply Services Exclusive licensing and supply agreements enabling pharmaceutical and biotech partners to commercialize therapies across multiple international markets. Examples include the AriBio AR1001 Alzheimer's therapy agreement and neuroscience collaborations with Fosun Pharma. Arcera provides regulatory, commercial, and market access expertise in emerging markets often not prioritized in early global launches.

Quantifiable outcome

  • Over 40% of UAE portfolio sales from domestically manufactured products
  • +3 more outcomes

Companies that use Arcera Life Sciences

Customer profile

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Arcera Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature4 records

Arcera Life Sciences partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered flagship, core and supporting.

  • M42flagshipStrategic or Co-development Partner · 3 June 2026M42 and Arcera signed a strategic MoU to advance biopharma localization, clinical development, and next-generation healthcare innovation in Abu Dhabi. The collaboration focuses on four pillars: genomics-informed therapeutic development, clinical development acceleration, advanced biobanking and regenerative medicine, and digital/AI-enabled transformation. Aligned with Department of Health Abu Dhabi's efforts to reinforce Emirate's position as a global hub for life sciences innovation.
  • Emirates Drug Establishment (EDE)coreStrategic or Co-development Partner · 5 May 2026MoU to strengthen pharmaceutical manufacturing capabilities in UAE through collaboration on local manufacturing, talent development, research and innovation, and strategic supply of medical products. Partnership supports Emiratization through training programs, technical exchanges, and workshops. Contributes to expanding local manufacturing capacity and strengthening UAE's strategic stockpile of medical products.
  • Fosun PharmaflagshipStrategic or Co-development Partner · 28 April 2026Arcera and Fosun Pharma signed MoU for long-term strategic collaboration focused on licensing, frontier technology incubation, and neuroscience innovation. Initial focus on licensing opportunities in oncology, neuroscience, rare diseases, and cardiometabolic disease. Exploration of joint ventures to localize cutting-edge biotechnology including biologics, radiopharmaceuticals, siRNA therapies, and cell and gene therapies in UAE. Aligned with China-UAE bilateral partnership and Abu Dhabi's Healthcare Life Sciences Vision 2030.
  • IQVIAsupportingImplementation/ SI/ Consulting Partner · 5 March 2026Partnership for implementation of new electronic Quality Management System (eQMS) consisting of six SmartSolve modules across 12 locations and corporate functions. Successfully implemented in nine months, strengthening quality, efficiency, and collaboration across manufacturing network.
  • NYU Abu DhabisupportingStrategic or Co-development Partner · 3 February 2026Academic partner hosting Arcera's Catalyst Forum at NYU Abu Dhabi, bringing together healthcare, academic, government, and industry leaders to discuss AI-powered healthcare transformation.
  • Department of Health Abu DhabicoreStrategic or Co-development Partner · 3 February 2026Collaboration through M42 partnership framework to leverage genomics data, support clinical development, and align with DoH's efforts to reinforce Abu Dhabi as global hub for life sciences innovation.
  • ISPOR UAE ChaptercoreStrategic or Co-development Partner · 31 January 2026Strategic MoU to advance health economics and outcomes research (HEOR) and health technology assessment (HTA) in UAE. Partnership focuses on enhancing research capabilities, building national expertise, and supporting evidence-based decision-making. Also includes collaboration on capacity building, career development, and mentorship. Supports UAE's ambition for healthcare excellence and life sciences leadership.
  • AriBiocoreOEM/ Whitelabel/ Licensing Partner · 10 June 2025Exclusive licensing and supply agreements for AR1001, an investigational therapy for Alzheimer's disease. Arcera will advance development and commercialize the therapy across multiple international markets. Collaboration reflects commitment to identifying promising therapies and accelerating patient access in markets often not prioritized in early stages of global product launches.
  • AribiocoreOEM/ Whitelabel/ Licensing Partner · 10 June 2025Exclusive licensing and supply agreements for AR1001, an investigational therapy for Alzheimer's disease. Arcera will advance development and commercialize across multiple international markets, particularly emerging markets not prioritized in early global launches.
  • LG ChemsupportingChannel Partner/ Reseller/ Distributor · 24 July 2024Exclusive agreement for marketing, commercialization, and distribution of Hyruan One in Brazil for osteoarthritis treatment, and Zemiglo and Zemimet SR (Zemiduo SR in Mexico) for type 2 diabetes in Latin American markets.

Scale indicators11 records

Recent moves6 records

Expansion highlights6 records

Arcera Life Sciences competitors and assessment

Company assessment

Direct peers

  • Aurobindo Pharma: Indian generic and specialty pharmaceutical company with strong emerging markets footprint. Comparable through large-scale branded generics, complex injectables manufacturing, and emerging markets distribution capability.
  • Aspen Pharmacare: South African pharmaceutical leader with operations across Africa, Latin America, and Asia. Comparable to Arcera through its emerging markets focus, branded generics portfolio, and complex manufacturing footprint in multiple jurisdictions.
  • Cipla: Indian pharmaceutical major with strong presence in Africa, emerging markets, and respiratory/chronotherapeutics. Directly comparable through its emerging markets commercial infrastructure, branded generics model, and ARV/oncology therapeutic focus areas.
  • Hikma Pharmaceuticals: Jordan-headquartered branded generics and injectables manufacturer with deep MEA and emerging markets presence. Directly comparable to Arcera through similar geographic focus, branded generics portfolio, and CDMO/injectables capabilities.
  • Dr. Reddy's Laboratories: Indian global pharmaceutical company with significant emerging markets presence across CIS, Africa, and Latin America. Comparable through diversified branded generics portfolio, CDMO services, and biosimilars pipeline.
  • Julphar (Gulf Pharmaceutical Industries): UAE-headquartered pharmaceutical manufacturer with MEA regional focus. Directly comparable to Arcera as the most prominent homegrown UAE pharma player with similar GCC distribution model and branded generics portfolio.
  • Lupin Pharmaceuticals: Indian pharmaceutical company with branded generics, complex generics, and biosimilars portfolio across emerging markets. Comparable through similar therapeutic focus areas and emerging markets commercial model.

Broad incumbents

  • Teva Pharmaceutical Industries: Global leader in generics and specialty medicines with extensive emerging markets presence. Comparable through broad generics portfolio and complex manufacturing, though operates at significantly larger scale and is publicly listed.
  • Sandoz (Novartis): Global generics and biosimilars business carved out of Novartis with worldwide distribution. Comparable through diversified generics portfolio and biologics manufacturing capabilities, though Sandoz is a global incumbent with much broader geographic reach.
  • Viatris: Global generics and biosimilars giant formed from Mylan-Upjohn merger with worldwide reach. Comparable through branded generics and off-patent originator medicines focus, though Viatris operates at much larger global scale across all major markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks5 records

Key highlights7 records

Customer concentration

Arcera Life Sciences social profiles

Digital presence

Arcera Life Sciences compliance and trust

Trust signal

Compliance3 records

Arcera Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Arcera Life Sciences leadership team

Management profile

Number of profiles

Profiles17 records

Arcera Life Sciences subsidiaries and ownership

Company hierarchy

Subsidiaries14 records

Arcera Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Arcera Life Sciences M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Arcera Life Sciences

What does Arcera Life Sciences do?

Arcera Life Sciences develops, manufactures, and commercializes over 2,000 branded generic and innovative pharmaceutical medicines across therapeutic areas including oncology, neuroscience, cardiometabolic, and rare diseases. The company operates through manufacturing facilities in eight countries and reaches patients in more than 120 markets via direct commercial operations, while also providing B2B contract manufacturing services to third-party pharmaceutical companies across 75 countries. Through licensing agreements and strategic partnerships, Arcera advances innovative therapies such as the AR1001 Alzheimer's treatment from AriBio.

Is Arcera Life Sciences a public or private company?

Arcera Life Sciences is a private company. It is classified as corporate owned and is currently operating.

When was Arcera Life Sciences founded?

Arcera Life Sciences was founded in 2024. It employs 501 to 1,000 people.

Where is Arcera Life Sciences based?

Arcera Life Sciences is headquartered in Abu Dhabi, United Arab Emirates, in the Middle East region.

How does Arcera Life Sciences make money?

Three revenue lines are on record. Pharmaceutical Product Sales are the primary driver. The others are contract Manufacturing Services and licensing and Supply Agreements.

Who are Arcera Life Sciences's main competitors?

Direct peers on record are Aurobindo Pharma, Aspen Pharmacare, Cipla, Hikma Pharmaceuticals, Dr. Reddy's Laboratories, Julphar (Gulf Pharmaceutical Industries) and Lupin Pharmaceuticals. Broad incumbents are Teva Pharmaceutical Industries, Sandoz (Novartis) and Viatris.

Does Arcera Life Sciences have an API?

No public API is recorded for Arcera Life Sciences.

What industry is Arcera Life Sciences in?

Arcera Life Sciences's product category is Pharmaceutical Manufacturing. Its primary akta.pro industry code is HLAIAAAE, Cardiometabolic Pharmaceuticals (Cardiovascular/Diabetes/Obesity), with a secondary code of HLAIAIAH, Rare Cardiovascular & Vascular Disorder Therapies. Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Mexico Business NewsDriving Life Sciences Growth Through Supply Chain ResilienceArcera, a life sciences company founded in 2023 by Abu Dhabi sovereign investor ADQ, operates in Mexico and Latin America through its acquired M8 and Acino entities, focusing on cardiometabolic, CNS, gastroenterology and orphan disease therapies. It plans a new Type 2 diabetes treatment by year-end, a CNS therapy around mid-2027, and regional manufacturing via AI-driven supply chain analytics.The Pharma LetterArcera’s sovereign-backed ambition to build a global life sciences bridgeArcera, a sovereign-backed healthcare group established by ADQ, is pursuing global expansion in the life sciences sector by leveraging its integrated portfolio of Acino, Amoun, and Birgi Mefar. The company aims to act as a commercial bridge between innovators in developed markets and high-growth regions such as Latin America, the Middle East, and Africa through strategic partnerships and targeted acquisitions.Financial PostArcera Life Sciences and Daewoong Expand Strategic Partnership to Bring Enavogliflozin to the Middle EastArcera Life Sciences and Daewoong Pharmaceutical announced the expansion of their strategic partnership to bring Enavogliflozin, a novel SGLT2 inhibitor for type 2 diabetes, to key Middle Eastern markets. The partnership builds on their existing collaboration that achieved Enavogliflozin approval in Mexico, with Arcera having acquired M8 Pharmaceuticals in December 2024 as part of its integrated platform. The expansion targets the Middle East where diabetes prevalence is among the highest globally, aiming to increase patient access to innovative cardiometabolic therapies across emerging markets.FinancialContent Business PageArcera Life Sciences and Daewoong Expand Strategic Partnership to Bring Enavogliflozin to the Middle EastArcera Life Sciences and Daewoong Pharmaceutical have expanded their strategic partnership to bring Enavogliflozin, a novel SGLT2 inhibitor for type 2 diabetes, to key Middle East markets including UAE, Saudi Arabia, Kuwait, Oman, Qatar, Bahrain, Egypt, and Iraq. The agreement builds on their prior collaboration that achieved Enavogliflozin approval in Mexico and combines Daewoong's R&D capabilities with Arcera's regulatory and commercial infrastructure across emerging markets where diabetes prevalence is among the highest globally. The companies will jointly work on regulatory, market access, and commercialization activities to support future launches across the agreed territories.GlobeNewswireArcera Life Sciences and Daewoong Expand Strategic Partnership to Bring Enavogliflozin to the Middle EastArcera Life Sciences and Daewoong Pharmaceutical announced an expansion of their strategic partnership to bring Enavogliflozin, Daewoong's novel SGLT2 inhibitor for type 2 diabetes, to key Middle Eastern markets including the UAE, Saudi Arabia, Kuwait, Oman, Qatar, Bahrain, Egypt, and Iraq. The partnership builds on their existing collaboration that recently achieved regulatory approval for the drug in Mexico. Both companies will jointly handle regulatory, market access, and commercialization activities to support launches across the agreed territories, where diabetes prevalence is among the highest globally.FinancialContent Business PageArticles from Arcera Life SciencesAriBio Co., Ltd. and Acino (part of Arcera) signed exclusive licensing, commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. The agreements cover Latin America and international markets, building on successful prior collaboration between the two companies in the region. The deal reinforces both companies' commitment to advancing innovative therapies for neurodegenerative and cardiometabolic diseases across global markets.ZawyaM42, Arcera partner to advance biopharma localisation, life sciences in Abu DhabiM42 and Arcera signed an MoU to collaborate on biopharma localisation and life sciences in Abu Dhabi. The partnership will use genomics data to assess disease prevalence and advance therapies for genetic and rare diseases. It aims to accelerate clinical development and improve patient access to innovative treatments.ZawyaM42, Arcera join hands to advance GenNext life sciences in Abu DhabiM42 and Arcera signed an MoU to collaborate on biopharma localization, clinical development, and next-generation healthcare in Abu Dhabi. The partnership will use genomics data to assess disease prevalence and accelerate therapies for genetic and rare diseases. It aims to build long-term capability within Abu Dhabi's life sciences ecosystem.ZawyaM42 and Arcera partner to advance biopharma localization and next generation life sciences in Abu DhabiM42 and Arcera signed a Memorandum of Understanding to collaborate on biopharma localization and next-generation life sciences in Abu Dhabi. The partnership will leverage genomics data and clinical development expertise to advance therapies for genetic and rare diseases. It aims to build long-term capability within Abu Dhabi's life sciences ecosystem.Khaleej TimesUAE pharma sector poised for strong growth as localisation, AI reshape industry dynamicsThe UAE pharmaceutical industry is entering a new growth phase driven by government policy, expanding healthcare demand, and AI adoption, with industry estimates suggesting the market could nearly double over the next decade. Local production has become a strategic priority following pandemic-era supply chain vulnerabilities, with companies like Arcera reporting that over 40% of UAE sales now come from domestically manufactured products. The UAE is also positioning itself as a regional life sciences hub, leveraging AI-powered process optimization and partnerships between industry, regulators, and academic institutions to build local capabilities.